Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
厄洛替尼联合林西替尼(OSI-906)或安慰剂治疗未接受过化疗且携带表皮生长因子受体激活突变的非小细胞肺癌患者的II期研究
期刊:Clinical Lung Cancer
影响因子:3.3
doi:10.1016/j.cllc.2016.07.007
Leighl, Natasha B; Rizvi, Naiyer A; de Lima, Lopes Gilberto Jr; Arpornwirat, Wichit; Rudin, Charles M; Chiappori, Alberto A; Ahn, Myung-Ju; Chow, Laura Q M; Bazhenova, Lyudmila; Dechaphunkul, Arunee; Sunpaweravong, Patrapim; Eaton, Keith; Chen, Jihong; Medley, Sonja; Poondru, Srinivasu; Singh, Margaret; Steinberg, Joyce; Juergens, Rosalyn A; Gadgeel, Shirish M